Sun Pharmaceutical Industries
Andheri Kurla Road
224 articles with Sun Pharmaceutical Industries
Sun Pharma Completes Acquisition of Concert Pharmaceuticals
Sun Pharmaceutical Industries Limited today announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc.
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Sun Pharmaceutical Industries Limited and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (“Concert”) today announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value.
Dr. Sandra Lee (AKA Dr. Pimple Popper) Joins Sun Pharma Awareness Campaign to Spotlight the Role of Hormones in the Skin as an Underlying Cause of Acne
Sun Pharmaceutical Industries, Inc. today announced the launch of "AH-ha!™ It's Acne Hormones," an awareness campaign featuring board-certified dermatologist Dr. Sandra Lee.
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announces it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE (collectively, Sun Pharmaceuticals) that involves both Aurinia and Sun Pharmaceuticals filing a joint motion to terminate the ongoing Inter Partes Review (IPR) directed at Aurinia’s U.S. Patent No. 10,286,036.
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
Sun Pharma Presents Phase 3 Data for WINLEVI® (clascoterone) cream 1% for the Topical Treatment of Acne Vulgaris at the AAD Annual Meeting
Sun Pharmaceutical Industries Limited today announced that the company's U.S. subsidiary presented data from two pivotal Phase 3 clinical trials of WINLEVI (clascoterone) cream 1% for the topical treatment of acne vulgaris (acne).
Sun Pharma to Present Clinical Data Abstracts for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis at 2022 AAD Annual Meeting
Sun Pharmaceutical Industries Inc., USA (Sun Pharma) today announced that five data abstracts for ILUMYA will be presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting, taking place March 25-29.
Cipher Pharmaceuticals Announces Extension of Distribution and Supply Agreement with Sun Pharmaceutical Industries Inc.
Cipher Pharmaceuticals Inc. announced that it has entered into a second amended and restated distribution and supply agreement with Sun Pharmaceutical Industries, Inc., a wholly owned subsidiary company of Sun Pharmaceutical Industries Limited, India.
Sun Pharma launches (Pr)CEQUA™ (cyclosporine ophthalmic solution 0.09% w/v), the first dry eye treatment with nanomicellar (NCELL™) technology*, in Canada
Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited "Sun Pharma" and includes its subsidiaries and/or associate companies), announced the launch of CEQUA, a new treatment for Canadians living with dry eye disease.
Sun Pharma and Cassiopea announce the expiry of the HSR Act process and the successful consummation of their Winlevi® (clascoterone cream 1%) agreement
Sun Pharmaceutical Industries Limited today announced the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act)
Sun Pharma and Cassiopea SpA Announce Signing of License and Supply Agreements for Winlevi® (clascoterone cream 1%) in US and Canada
Sun Pharmaceutical Industries Ltd., "Sun Pharma" and includes its subsidiaries and/or associate companies) and Cassiopea SpA, a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action to address long-standing essential dermatological conditions, announced the signing of License and Supply Agreements for Winlevi® in the United States and Canada.
Here’s a look at some of the top COVID-19-related stories for today.
Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical
Corcept Therapeutics Incorporated today announced that it has entered into an agreement with Sun Pharmaceutical Industries Limited and related entities ("Sun") resolving patent litigation related to Korlym.
Sun Pharma to Present Clinical Data Abstracts for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis at the AAD Virtual Meeting Experience 2021
The data abstracts to be presented at AAD VMX reinforce that ILUMYA is a long-lasting biologic treatment choice for patients with moderate-to-severe plaque psoriasis through five years of continuous treatment.
Parents are Very Worried About the Effects of Severe Acne on their Teenage Children as Reported in a New Survey
Findings reflect heightened stress on families as teens cope with isolation and embarrassment; remote schooling eases some worries but exacerbates others
Sun Pharma Announces Drizalma Sprinkle™ (duloxetine delayed-release capsules) is Now Covered by Most Medicare Part D Plans
Coverage for novel formulation of duloxetine now offered to 91% of lives in top 10 Medicare Part D plans Broader access to Drizalma Sprinkle™ reinforces Sun Pharma's commitment to the 40% of American adults who cannot or will not swallow solid medication forms
Sun Pharma Launches Website for its Long-Term Care Portfolio in the U.S.
New website highlights the efficacy and safety profile for each product, while also educating healthcare providers and patients about our intent to mitigate risks associated with improper medication manipulation
Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis
ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis
Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of RIOMET ER™ (metformin hydrochloride for extended-release oral suspension) Due to N-Nitrosodimethylamine (NDMA) Content Above the Acceptable Daily Intake (ADI) Limit
Sun Pharmaceutical Industries, Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. is voluntarily recalling one lot of RIOMET ER™, 500 mg per 5 mL to the consumer level.
Orexo commences patent infringement litigation against Sun Pharmaceutical
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has filed a patent infringement action in the United States District Court for the District of New Jersey with docket number 3:20-cv-12588, against Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc., and Sun Pharmaceutical Indu